Genetic metamorphosis of herpes simplex virus-1 into a biological therapeutic for human cancer

Expert Opinion on Biological Therapy

Volumn 3, Issue 1, 2003, Pages 113-125

  Mohr, Ian ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Herpes simplex virus 1 34.5 mutants; Oncolytic replication competent virus

Indexed keywords

1716; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; G 207; G 47D; GENE PRODUCT; IMMUNOSUPPRESSIVE AGENT; MGH 1; NV 1020; ONCOLYTIC VIRUS; PROTEIN GAMMA 34.5; R 3616; R 5126; R 7020; SNAKE VENOM; UNCLASSIFIED DRUG;

CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; ENCEPHALITIS; GAMMA 34.5 GENE; GENE MUTATION; GENETIC MANIPULATION; HERPES SIMPLEX VIRUS 1; HUMAN; INOCULATION; METAMORPHOSIS; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIMATE; REVIEW; SIDE EFFECT; TUMOR IMMUNITY; VIRUS ATTENUATION; VIRUS GENE; VIRUS MUTANT; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS VIRULENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL THERAPY; HERPESVIRUS 1, HUMAN; HUMANS; NEOPLASMS; VIRUS REPLICATION;

HUMAN HERPESVIRUS 1; PRIMATES; SERPENTES; SIMPLEXVIRUS;

EID: 0037319231     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.3.1.113     Document Type: Review

References (74)

1. KIRN DH: Replication-selective microbiological agents: fighting cancer with germ warfare. J. Clin. Invest. (2000) 105:837-839.
2. ROIZMAN B, KNIPE D: Herpes simplex viruses and their replication. In Fields virology, 4th ed., vol. 2. Knipe DM & Howley PM (Eds.), Lippincott, Williams & Wilkins, Philadelphia, Pa. (2001): 2399-2460.
3. MARTUZA RL, MALICK A, MARKERT JM, RUFFNER KL, COEN DM: Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science (1991) 252:854-856.
4. FIELD HJ, WILDY P: The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice. J. Hyg. (London) (1978) 81:267-277.
5. JAMIESON AT, GENTRY GA, SUBAKSHARPE JH: Induction of both thymidine and deoxycytidine kinase activity by herpes viruses. J. Gen. Virol. (1974) 24:465-480.
6. FIELD HJ, DARBY G: Pathogenicity in mice of strains of herpes simplex virus which are resistant to acyclovir in vitro and in vivo. Antimicrob. Agents Chemother. (1980) 17:209-216.
7. TENSER RB, MILLER RL, RAPP F: Trigeminal ganglion infection by thymidine kinase-negative mutants of herpes simplex virus. Science (1979) 205:915-917.
8. COEN DM, KOSZ-VNENCHAK M, JACOBSON JG et al.: Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc. Natl. Acad. Sci. USA (1989) 86:4736-4740.
9. MARKERT JM, MALICK A, COEN DM, MARTUZA RL: Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery (1993) 32:597-603.
10. MINETA T, RABKIN SD, MARTUZA RL: Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. (1994) 54:3963-3966.
11. CHOU J, KERN ER, WHITLEY RJ, ROIZMAN B: Mapping of herpes simplex virus-1 neurovirulence to gamma (1) 34.5, a gene nonessential for growth in culture. Science (1990) 250:1262-1266.
12. MACLEAN AR, UL-FAREED M, ROBERTSON L, HARLAND J, BROWN SM: Herpes simplex virusType 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence. J. Gen. Virol. (1991) 72:631-639.
13. BOLOVAN CA, SAWTELL NM, THOMPSON RL: ICP34.5 mutants of herpes simplex virusType 1 strain 17syn+ are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell cultures. J. Virol. (1994) 68:48-55.
14. MINETA T, RABKIN SD, YAZAKI T, HUNTER WD, MARTUZA RL: Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. (1995) 1:938-943.
15. HUNTER WD, MARTUZA RL, FEIGENBAUM F et al: Attenuated, replication-competent herpes simplex virus Type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J. Virol. (1999) 73:6319-6326.
16. MARKERT JM, MEDLOCK MD, RABKIN SD et al.: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a Phase I trial. Gene Ther. (2000) 7:867-874.
17. RAMPLING R, CRUICKSHANK G, PAPANASTASSIOU V et al.: Toxicity evaluation of replication-competent herpes simple virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. (2000) 7:859-866.
18. SUNDARESAN P, HUNTER WD, MARTUZA RL, RABKIN SD: Attenuated, replication-competent herpes simplex virus Type 1 mutant G207: safety evaluation in mice. J. Virol. (2000) 74:3832-3841.
19. CHAMBERS R, GILLESPIE GY, SOROCEANU L et al.: Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc. Natl. Acad. Sci. USA (1995) 92:1411-1415.
20. KESARI S, RANDAZZO BP, VALYINAGY T et al. Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab. Invest. (1995) 73:636-648.
21. ANDREANSKY SS, HE B, GILLESPIE GY et al.: The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc. Natl. Acad. Sci. USA (1996) 93:11313-11318.
22. ANDREANSKY S, SOROCEANU L, FLOTTE ER et al.: Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res. (1997) 57:1502-1509.
23. RANDAZZO BP, KESARI S, GESSER RM et al.: Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant. Virology (1995) 211:94-101.
24. KESARI S, LASNER TM, BALSARA KR et al.: A neuroattenuated ICP34.5-deficient herpes simplex virusType 1 replicates in ependymal cells of the murine central nervous system. J. Gen. Virol. (1998) 79:525-536.
25. LASNER TM, TAL-SINGER R, KESARI S, LEE VM, TROJANOWSKI JQ, FRASER NW: Toxicity and neuronal infection of a HSV-1 ICP34.5 mutant in nude mice. J. Neurovirol. (1998) 4:100-105.
26. MARKOVITZ NS, BAUNOCH D, ROIZMAN B: The range and distribution of murine central nervous system cells infected with the gamma(1)34.5-mutant of herpes simplex virus 1. J. Virol. (1997) 71:5560-5569.
27. KRAMM CM, CHASE M, HERRLINGER U et al: Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum. Gene Ther. (1997) 8:2057-2068.
28. PYLES RB,WARNICK RE, CHALK CL, SZANTI BE, PARYSEK LM: A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum. Gene Ther. (1997) 8:533-544.
29. CHOU J, ROIZMAN B: The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells. Proc. Natl. Acad. Sci. USA (1992) 89:3266-3270.
30. CHOU J, CHEN JJ, GROSS M, ROIZMAN B: Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma (1)34.5-mutants of herpes simplex virus 1. Proc. Natl. Acad. Sci. USA (1995) 92:10516-10520.
31. KAUFMAN RJ: Double-stranded RNA-activated protein kinase PKR. In Translational Control. Sonenberg N, Hershey JWB & Mathews MB (Eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (2000): 503-528.
32. PETERS GA, KHOO D, MOHR I, SEN G: Inhibition of PACT mediated activation of PKR by the herpes simplex virus type 1 Us11 protein. J. Virol. (2002) 76:11054-11064.
33. SCHNEIDER RJ, MOHR I: Translation initiation and viral tricks. Trends Biochem. Sci. (2003) In press.
34. HE B, GROSS M, ROIZMAN B: The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc. Natl. Acad. Sci. USA (1997) 94:843-848.
35. NOVOA I, ZENG H, HARDING HP, RON D: Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2 alpha. J. Cell Biol. (2001) 153:1011-1022.
36. LEIB DA, MACHALEK MA, WILLIAMS BR, SILVERMAN RH, VIRGIN HW: Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene. Proc. Natl. Acad. Sci. USA (2000) 97:6097-6101.
37. MOHR I, GLUZMAN Y: A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function. EMBO J. (1996) 15:4759-4766.
38. YORK IA, ROOP C, ANDREWS DW, RIDDELL SR, GRAHAM FL, JOHNSON DC: A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell (1994) 77:525-535.
39. MULVEY M, POPPERS J, LADD A, MOHR I: A herpesvirus ribosome-associated, RNA-binding protein confers a growth advantage upon mutants deficient in a GADD34-related function. J. Virol. (1999) 73:3375-3385.
40. POPPERS J, MULVEY M, KHOO D, MOHR I: Inhibition of PKR activation by the proline-rich RNA binding domain of the herpes simplex virusType 1 Us11 protein. J. Virol. (2000) 74:11215-11221.
41. KHOO D, PEREZ C, MOHR I: Characterization of RNA determinants recognized by the arginine- and proline-rich region of Us11, a herpes simplex virusType 1 encoded double-stranded RNA binding protein that prevents PKR activation. J. Virol. (2002) 76:11971-11981.
42. POPPERS J, MULVEY M, PEREZ C, KHOO D, MOHR I: Identification of a lytic Epstein-Barr virus gene product that can regulate PKR activation. J. Virol. (2003) 77:228-236.
43. CASSADY KA, GROSS M: The herpes simplex virusType 1 U(S)11 protein interacts with protein kinase R in infected cells and requires a 30-amino-acid sequence adjacent to a kinase substrate domain. J. Virol. (2002) 76:2029-2035.
44. MOHR I, STERNBERG D, WARD S, LEIB D, MULVEY M, GLUZMAN Y: A herpes simplex virusType 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals. J. Virol. (2001) 75:5189-5196.
45. TANEJA S, MACGREGOR J, MARKUS S, HA S, MOHR I: Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells. Proc. Natl. Acad. Sci. USA (2001) 98:8804-8808.
46. TODO T, MARTUZA RL, RABKIN SD, JOHNSON PA: Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc. Natl. Acad. Sci. USA (2001) 98:6396-6401.
47. HILL A, JUGOVIC P, YORK I et al.: Herpes simplex virus turns off the TAP to evade host immunity. Nature (1995) 375:411-415.
48. HE B, CHOU J, BRANDIMARTI R, MOHR I, GLUZMAN Y, ROIZMAN B: Suppression of the phenotype of gamma(1)34.5- herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene. J. Virol. (1997) 71:6049-6054.
49. CHUNG RY, SAEKI Y, CHIOCCA EA: B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward rumor and cycling cells. J. Virol. (1999) 73:7556-7564.
50. MEIGNIER B, LONGNECKER R, ROIZMAN B: In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J. Infect. Dis. (1988) 158:602-614.
51. MEIGNIER B, MARTIN B, WHITLEY RJ, ROIZMAN B: In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J. Infect. Dis. (1990) 162:313-321.
52. ADVANI SJ, CHUNG SM, YAN SY et al.: Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res. (1999) 59:2055-2058.
53. KNIPE DM, RUYECHAN WT, ROIZMAN B, HALLIBURTON IW: Molecular genetics of herpes simplex virus: demonstration of regions of obligatory and nonobligatory identity within diploid regions of the genome by sequence replacement and insertion. Proc Natl. Acad. Sci. USA (1978) 75:3896-3900.
54. PARKER JN, GILLESPIE GY, LOVE CE, RANDALL S, WHITLEY RJ, MARKERT JM: Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc. Natl. Acad. Sci. USA (2000) 97:2208-2213.
55. ADVANI SJ, SIBLEY GS, SONG PY et al.: Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors. Gene Ther. (1998) 5:160-165.
56. BRADLEY JD, KATAOKA Y, ADVANI S et al.: Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus. Clin. Cancer Res. (1999) 5:1517-1522.
57. STANZIALE SF, PETROWSKY H, JOE JK et al.: Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase. Surgery (2002) 132:353-359.
58. CHAHLAVI A, TODO T, MARTUZA RL, RABKIN SD: Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia (1999) 1:162-169.
59. IKEDA K, ICHIKAWA T, WAKIMOTO H et al.: Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat. Med. (1999) 5:881-887.
60. KEDA K, WAKIMOTO H, ICHIKAWA T et al.: Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J. Virol. (2000) 74:4765-4775.
61. JORGENSEN TJ, KATZ S, WITTMACK EK et al.: Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer. Neoplasia (2001) 3:451-456.
62. WU A, MAZUMDER A, MARTUZA RL et al.: Biological purging of breast cancer cells using an attenuated replication-competent herpes simplex virus in human hematopoietic stem cell transplantation. Cancer Res. (2001) 61:3009-3015.
63. WALKER JR, MCGEAGH KG, SUNDARESAN P, JORGENSEN TJ, RABKIN SD, MARTUZA RL: Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum. Gene Ther. (1999) 10:2237-2243.
64. WONG RJ, JOE JK, KIM SH, SHAH JP, HORSBURGH B, FONG Y: Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases. Hum. Gene Ther (2002) 13:1213-1223.
65. HERRLINGER U, KRAMM CM, ABOODY-GUTERMAN KS et al.: Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector. Gene Ther. (1998) 5:809-819.
66. CHAHLAVI A, RABKIN S, TODO T, SUNDARESAN P, MARTUZA R: Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in imm unocompetent mice. Gene Ther. (1999) 6:1751-1758.
67. DELMAN KA, BENNETT JJ, ZAGER JS et al.: Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. Hum. Gene Ther. (2000) 11:2465-2472.
68. TODA M, RABKIN SD, KOJIMA H, MARTUZA RL: Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum. Gene Ther. (1999) 10:385-393.
69. TODO T, RABKIN SD, SUNDARESAN P et al.: Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum. Gene Ther. (1999) 10:2741-2755.
70. PAPANASTASSIOU V, RAMPLING R, FRASER M et al.: The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther. (2002) 9:398-406.
71. MACKIE RM, STEWART B, BROWN SM: Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet (2001) 357:525-526.
72. CASSADY KA, GROSS M, GILLESPIE GY, ROIZMAN B: Secondsite mutation outside of the Us10-12 domain of ΔT34.5 herpes simplex virus 1 recombinant blocks the shutoff of protein synthesis induced by activated protein kinase R and partially restores neurovirulence. J. Virol. (2002) 76:942-949.
73. GOLDSMITH K, CHEN W, JOHNSON DC, HENDRICKS RL: Infected cell protein (ICP)47 enhances herpes simplex virus neurovirulence by blocking the CD8+ T cell response. J. Exp. Med. (1998) 187:341-348.
74. AHN K, MEYER TH, UEBEL S et al.: Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47. EMBO J. (1996) 15:3247-3255.